Доклинические исследования нейротоксических свойств новых лекарственных препаратов in vivo
Аннотация
Об авторах
Н. В. ЕреминаРоссия
Еремина Наталья Вахитовна, канд. биол. наук
Балтийская ул., д. 8, Москва, 125315
Л. Г. Колик
Россия
Колик Лариса Геннадьевна, д-р биол. наук, профессор РАН
Балтийская ул., д. 8, Москва, 125315
Р. У. Островская
Россия
Островская Рита Ушеровна, д-р мед. наук, профессор
Балтийская ул., д. 8, Москва, 125315
А. Д. Дурнев
Россия
Дурнев Андрей Дмитриевич, д-р мед. наук, профессор, член-корр. РАН
Балтийская ул., д. 8, Москва, 125315
Список литературы
1. Kerbrat A, Ferré JC, Fillatre P, Ronziere T, Vannier S, Carsin-Nicol B, et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N Engl J Med. 2016;375(18):1717–25. https://doi.org/10.1056/NEJMoa1604221
2. Valentin JP, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods. 2008;58(2):77–87. https://doi.org/10.1016/j.vascn.2008.05.007
3. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite M, Pangalos MN. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419–31. https://doi.org/10.1038/nrd4309
4. Walker AL, Imam SZ, Roberts RA. Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration. Exp Biol Med (Maywood). 2018;243(13):1037–45. https://doi.org/10.1177/1535370218801309
5. Costa LG. Overview of neurotoxicology. Curr Protoc Toxicol. 2017;74(1):11.1.1–11.1.11. https://doi.org/10.1002/cptx.36
6. Fang H, Harris SC, Liu Z, Zhou G, Zhang G, Xu J, et al. FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science. Drug Discov Today. 2016;21(10):1566–70. https://doi.org/10.1016/j.drudis.2016.06.006
7. Pugsley MK, Authier S, Curtis MJ. Principles of safety pharmacology. Br J Pharmacol. 2008;154(7):1382–99. https://doi.org/10.1038/bjp.2008.280
8. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968;13(3):222–57. https://doi.org/10.1007/bf00401402
9. Moser VC. Screening approaches to neurotoxicity: A functional observational battery. J Am Coll Toxicol. 1989;8(1):85–93. https://doi.org/10.3109%2F10915818909009095
10. Moser VC, McCormick JP, Creason JP, MacPhail RC. Comparison of chlordimeform and carbaryl using a functional observational battery. Fundam Appl Toxicol. 1988;11(2):189–206. https://doi.org/10.1016/0272-0590(88)90144-3
11. Moser VC, MacPhail RC. Neurobehavioral effect of triadimefon, a triazole fungicide, in male and female rats. Neurotoxicol Teratol. 1989;11(3):285–93. https://doi.org/10.1016/0892-0362(89)90071-8
12. Ewart L, Milne A, Adkins D, Benjamin A, Bialecki R, Chen Y, et al. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions. J Pharmacol Toxicol Methods. 2013;68(1):30–43. https://doi.org/10.1016/j.vascn.2013.04.008
13. Gauvin DV, Yoder JD, Holdsworth DL, Harter ML, May JR, Cotey N, et al. The standardized functional observational battery: Its intrinsic value remains in the instrument of measure: the rat. J Pharmacol Toxicol Methods. 2016;82:90–108. https://doi.org/10.1016/j.vascn.2016.08.001
14. Mathiasen JR, Moser VC. The Irwin test and functional observational battery (FOB) for assessing the effects of compounds on behavior, physiology, and safety pharmacology in rodents. Curr Protoc Pharmacol. 2018;83(1):e43. https://doi.org/10.1002/cpph.43
15. Redfern WS, Dymond A, Strang I, Storey S, Grant C, Marks L, et al. The functional observational battery and modified Irwin test as global neurobehavioral assessments in the rat: Pharmacological validation data and a comparison of methods. J Pharmacol Toxicol Methods. 2019;98:106591. https://doi.org/10.1016/j.vascn.2019.106591
16. Roux S, Sablé E, Porsolt RD. Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function. Curr Protoc Pharmacol. 2005;Chapter 10:Unit 10.10. https://doi.org/10.1002/0471141755.ph1010s27
17. Moser VC. Functional assays for neurotoxicity testing. Toxicol Pathol. 2011;39(1):36–45. https://doi.org/10.1177/0192623310385255
18. Gauvin DV, Zimmermann ZJ. FOB vs modified Irwin: What are we doing? J Pharmacol Toxicol Methods. 2019;97:24–8. https://doi.org/10.1016/j.vascn.2019.02.008
19. Moser VC. Applications of a neurobehavioral screening battery. Int J Toxicol. 1991;10(6):661–9. https://doi.org/10.3109/10915819109078658
20. Mead AN, Amouzadeh HR, Chapman K, Ewart L, Giarola A, Jackson SJ, et al. Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials. Regul Toxicol Pharmacol. 2016;80:348–57. https://doi.org/10.1016/j.yrtph.2016.05.002
21. Fonck C, Easter A, Pietras MR, Bialecki RA. CNS adverse effects: From functional observation battery/irwin tests to electrophysiology. Handb Exp Pharmacol. 2015;229:83–113. https://doi.org/10.1007/978-3-662-46943-9_4
22. Lynch JJ 3rd, Castagné V, Moser PC, Mittelstadt SW. Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J Pharmacol Toxicol Methods. 2011;64(1):74–80. https://doi.org/10.1016/j.vascn.2011.03.003
23. Himmel HM, Delaunois A, Deurinck M, Dinklo T, Eriksson Faelker TM, Habermann C, et al. Variability of non-clinical behavioral CNS safety assessment: An intercompany comparison. J Pharmacol Toxicol Methods. 2019;99:106571. https://doi.org/10.1016/j.vascn.2019.03.002
24. Бессалова ЕЮ. Методика исследования поведения крыс в условиях «Открытого поля». Нейронауки. 2011;7(2):106–9.
25. Górska AM, Kamińska K, Wawrzczak-Bargieła A, Costa G, Morelli M, Przewlocki R, et al. Neurochemical and neurotoxic effects of MDMA (Ecstasy) and Caffeine after chronic combined administration in mice. Neurotox Res. 2018;33(3):532–48. https://doi.org/10.1007/s12640017-9831-9
26. Umezawa M, Onoda A, Korshunova I, Jensen A, Koponen IK, Jensen KA, et al. Maternal inhalation of carbon black nanoparticles induces neurodevelopmental changes in mouse offspring. Part Fibre Toxicol. 2018;15(1):36. https://doi.org/10.1186/s12989-018-0272-2
27. Walsh RN, Cummins RA. The open-field test: a critical review. Psychol Bull. 1976;83(3):482–504. PMID: 17582919
28. Stanford SC. The open field test: reinventing the wheel. J Psychopharmacol. 2007;21(2):134–5. https://doi.org/10.1177/0269881107073199
29. Blizard DA, Takahashi A, Galsworthy MJ, Martin B, Koide T. Test standardization in behavioural neuroscience: a response to Stanford. J Psychopharmacol. 2007;21(2):136–9. https://doi.org/10.1177/0269881107074513
30. Bondy SC, Campbell A. Developmental neurotoxicology. J Neurosci Res. 2005;81(5):605–12. https://doi.org/10.1002/jnr.20589
31. Ornoy A. Valproic acid in pregnancy: How much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28(1):1–10. https://doi.org/10.1016/j.reprotox.2009.02.014
32. Veroniki AA, Rios P, Cogo E, Straus SE, Finkelstein Y, Kealey R, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open. 2017;7(7):e017248. https://doi.org/10.1136/bmjopen-2017-017248
33. Bauer AZ, Kriebel D, Herbert MR, Bornehag CG, Swan SH. Prenatal paracetamol exposure and child neurodevelopment: A review. Horm Behav. 2018;101:125–47. https://doi.org/10.1016/j.yhbeh.2018.01.003
34. Healy D, Le Noury J, Mangin D. Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/ spectrum disorders: A systematic review of epidemiological and physiological evidence. Int J Risk Saf Med. 2016;28(3):125–41. https://doi.org/10.3233/JRS-160726
35. Sie SD, Wennink JM, van Driel JJ, Winkel AGW, Boer K, Casteelen G, van Weissenbruch MM. Maternal use of SSRIs, SNRIs and NaSSAs: Practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed. 2012;97(6):F472–6 [Erratum. Arch Dis Child Fetal Neonatal Ed. 2013;98(2):F180]. https://doi.org/10.1136/archdischild-2011-214239
36. Manson JE. Prenatal exposure to sex steroid hormones and behavioral/cognitive outcomes. Metabolism. 2008;57(Suppl 2):S16–21. https://doi.org/10.1016/j.metabol.2008.07.010
37. Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006;368(9553):2167–78. https://doi.org/10.1016/S0140-6736(06)69665-7
38. Grandjean P, Landrigan PJ. Neurobehavioural effects of developmental toxicity. Lancet Neurol. 2014;13(3):330–8. https://doi.org/10.1016/S1474-4422(13)70278-3
39. Liu L, Zhang D, Rodzinka-Pasko JK, Li YM. Environmental risk factors for autism spectrum disorders. Nervenarzt. 2016;87 (Suppl 2):55–61. https://doi.org/10.1007/s00115-016-0172-3
40. London Z, Albers JW. Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin. 2007;25(1):257–76. https://doi.org/10.1016/j.ncl.2006.10.001
41. Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol. 2005;28(1):38–49. https://doi.org/10.1097/01.wnf.0000150871.52253.b7
42. Vlisides P, Xie Z. Neurotoxicity of general anesthetics: an update. Curr Pharm Des. 2012;18(38):6232–40. https://doi.org/10.2174/138161212803832344
43. Лебедев ИВ, Плескачева МГ, Анохин КВ. Анализ поведения мышей линии C57BL/6 в аренах «открытого поля» разного размера. Журнал высшей нервной деятельности им. И.П. Павлова. 2012;62(4):485–96.
44. Suter L, Babiss LE, Wheeldon EB. Toxicogenomics in predictive toxicology in drug development. Chem Biol. 2004;11(2):161–71. https://doi.org/10.1016/j.chembiol.2004.02.003
45. Vorhees CV, Williams MT. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1(2):848–58. https://doi.org/10.1038/nprot.2006.116
46. Rosenfeld CS, Ferguson SA. Barnes maze testing strategies with small and large rodent models. J Vis Exp. 2014;(84):e51194. https://doi.org/10.3791/51194
47. Leger M, Quiedeville A, Bouet V, Haelewyn B, Boulouard M, Schumann-Bard P, Fleret T. Object recognition test in mice. Nat Protoc. 2013;8(12):2531–7. https://doi.org/10.1038/nprot.2013.155
48. Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study “recognition memory”. Nat Protoc. 2006;1(3):1306–11. https://doi.org/10.1038/nprot.2006.205
49. Daldrup T, Remmes J, Lesting J, Gaburro S, Fendt M, Meuth P, et al. Expression of freezing and fear-potentiated startle during sustained fear in mice. Genes Brain Behav. 2015;14(3):281–91. https://doi.org/10.1111/gbb.12211
50. Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1(4):1671–9. https://doi.org/10.1038/nprot.2006.275
51. Hölter SM, Garrett L, Einicke J, Sperling B, Dirscherl P, Zimprich A, et al. Assessing cognition in mice. Curr Protoc Mouse Biol. 2015;5(4):331–58. https://doi.org/10.1002/9780470942390.mo150068
52. Островская РУ, Гудашева ТА. Выявление активности ноотропов по показателю острого угашения ориентировочной реакции. Бюллетень экспериментальной биологии и медицины. 1991;111(5):498–500. https://doi.org/10.1007/BF00841006
53. Бондаренко НА. Изучение возможности формирования целенаправленного поведения у крыс с «одной пробы» в тесте «Экстраполяционное избавление». В кн.: Харитонов АН, ред. Эволюционная и сравнительная психология в России: традиции и перспективы. М.: Институт психологии РАН. 2013. C. 122–30.
54. Андреева АК, Дубина ДШ, Фельдман БВ, Горшков ДА, Галимзянова АХ. Влияние эритропоэтина на психомоторную активность. Естественные науки. 2009;(4):87–9.
55. Багметова ВВ, Бородкина ЛЕ, Тюренков ИН, Берестовицкая ВМ, Васильева ОС. Сравнительное экспериментальное изучение ноотропных свойств аналога ГАМК фенибута и его метилового эфира. Фундаментальные исследования. 2011;10(3):467–71.
56. Гайнетдинов АР, Фесенко ЗС, Хисматуллина ЗР. Поведенческие изменения у крыс-гетерозигот по нокауту гена дофаминового транспортера DAT. Биомедицина. 2020;16(1):82–8. https://doi.org/10.33647/2074-5982-16-1-82-88
57. Соломина АС, Шредер ЕД, Колик ЛГ, Дурнев АД. Исследование влияния фабомотизола на поведенческие нарушения у потомства крыс, подвергнутых действию табачного дыма и алкоголя. Фармакокинетика и фармакодинамика. 2018;(2):3–11. https://doi.org/10.24411/2587-7836-2018-10008
58. Whishaw IQ, Tomie JA. Of mice and mazes: Similarities between mice and rats on dry land but not water mazes. Physiol Behav. 1996;60(5):1191–7. https://doi.org/10.1016/s0031-9384(96)00176-x
59. Frick KM, Stillner ET, Berger-Sweeney J. Mice are not little rats: Species differences in a one-day water maze task. Neuroreport. 2000;11(16):3461–5. https://doi.org/10.1097/00001756-20001109000013
60. Yoshida M, Goto K, Watanabe S. Task-dependent strain difference of spatial learning in C57BL/6N and BALB/c mice. Physiol Behav. 2001;73(1–2):37–42. https://doi.org/10.1016/s0031-9384(01)00419-x
61. Grissom EM, Hawley WR, Hodges KS, Fawcett-Patel JM, Dohanich GP. Biological sex influences learning strategy preference and muscarinic receptor binding in specific brain regions of prepubertal rats. Hippocampus. 2013;23(4):313–22. https://doi.org/10.1002/hipo.22085
62. Hawley WR, Grissom EM, Barratt HE, Conrad TS, Dohanich GP. The effects of biological sex and gonadal hormones on learning strategy in adult rats. Physiol Behav. 2012;105(4):1014–20. https://doi.org/10.1016/j.physbeh.2011.11.021
63. Maguire EA, Burgess N, Donnett JG, Frackowiak RS, Frith CD, O’Keefe J. Knowing where and getting there: a human navigation network. Science. 1998;280(5365):921–4. https://doi.org/10.1126/science.280.5365.921
64. Parrella E, Maxim T, Maialetti F, Zhang L, Wan J, Wei M, et al. Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer’s disease mouse model. Aging Cell. 2013;12(2):257–68. https://doi.org/10.1111/acel.12049
65. Méndez-López M, Méndez M, Arias J, Arias JL. Effects of a high protein diet on cognition and brain metabolism in cirrhotic rats. Physiol Behav. 2015;149:220–8. https://doi.org/10.1016/j.physbeh.2015.05.038
66. Roberts AJ, Hedlund PB. The 5-HT(7) receptor in learning and memory. Hippocampus. 2012;22(4):762–71. https://doi.org/10.1002/hipo.20938
67. Olvera-Cortés E, Pérez-Vega MI, Barajas-López G, Del Angel-Meza AR, González-Burgos I, Feria-Velasco A. Place learning impairment in chronically tryptophan-restricted rats. Nutr Neurosci. 1998;1(3):223–35. https://doi.org/10.1080/1028415X.1998.11747232
68. Yagi S, Galea LAM. Sex differences in hippocampal cognition and neurogenesis. Neuropsychopharmacology. 2019;44(1):200–13. https://doi.org/10.1038/s41386-018-0208-4
69. Barron AM, Tokunaga M, Zhang MR, Ji B, Suhara T, Higuchi M. Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET. J Neuroinflammation. 2016;13(1):221. https://doi.org/10.1186/s12974-016-0700-x
70. Ledreux A, Wang X, Schultzberg M, Granholm AC, Freeman LR. Detrimental effects of a high fat/high cholesterol diet on memory and hippocampal markers in aged rats. Behav Brain Res. 2016;312:294–304. https://doi.org/10.1016/j.bbr.2016.06.012
Рецензия
Для цитирования:
Еремина Н.В., Колик Л.Г., Островская Р.У., Дурнев А.Д. Доклинические исследования нейротоксических свойств новых лекарственных препаратов in vivo. Ведомости Научного центра экспертизы средств медицинского применения . 2020;10(3):164-176. https://doi.org/10.30895/1991-2919-2020-10-3-164-176
For citation:
Eremina N.V., Kolik L.G., Ostrovskaya R.U., Durnev A.D. Preclinical in vivo Neurotoxicity Studies of Drug Candidates. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products . 2020;10(3):164-176. (In Russ.) https://doi.org/10.30895/1991-2919-2020-10-3-164-176